DR. PETER C FUNG, M.D., F.A.C.P.
Psychiatric at Arques Ave, Sunnyvale, CA

7256011, Aug 14, 2007

Jan 28, 2003

10/353908

Pyare Khanna - Fremont CA, US
Peter Fung - Sunnyvale CA, US
Joseph L. Horecka - Fremont CA, US

Discoverx Inc. - Fremont CA

C12Q 1/37

435 23

A protein reagent is provided for measuring protease enzyme activity in a sample. The protein reagent comprises two inhibition entities joined by a linker comprised of an indicator enzyme donor and an amino acid sequence susceptible to enzymatic cleavage. The protein reagent is substantially inhibited from binding to the cognate enzyme acceptor fragment, while the product of the enzymatic cleavage binds to the cognate enzyme acceptor fragment to form a functional indicator enzyme. The indicator enzyme activity is related to the protease enzyme activity of the sample.

2007010, May 10, 2007

Oct 24, 2006

11/585498

Peter Fung - Sunnyvale CA, US
Philip Kobel - Campbell CA, US
Richard Eglen - Los Altos CA, US

G01N 33/567, C12Q 1/34

435007200, 435018000

Methods and compositions are provided for determining intracellular translocation of proteins employing β-galactosidase fragments that independently complex to form an active enzyme. Cells are used having two fusion constructs: one fragment bound to a protein of interest; and the other fragment bound to a compartment localizing signal. The cells are used to screen compounds for their effect on translocation, where a substrate containing high ionic strength solution is used for detection of the enzyme complex.

7608415, Oct 27, 2009

Jun 29, 2005

11/170123

Joseph Horecka - Fremont CA, US
Peter Fung - Sunnyvale CA, US
Richard M. Eglen - Los Altos CA, US

Discoverx Corporation - Fremont CA

C12Q 1/34, C12Q 1/00, C12N 9/24

435 18, 435 4, 435200

Improved methods of determining the intracellular state of a protein as well as modifications of the protein are provided by introducing a surrogate fusion protein comprising a member of an enzyme fragment complementation complex and a target protein. After exposing cells transformed with the surrogate fusion protein to a change in environment, e. g. a candidate drug, the cells are lysed, the lysate separated into fractions or bands, conveniently by gel electrophoresis and transferring the proteins by Western blot to a membrane. The bands on the membrane are developed using the other member of the enzyme fragment complementation complex and a substrate providing a detectable signal. The method is found to provide high sensitivity and the ability to observe modifications of the target protein.

2004010, Jun 3, 2004

Oct 20, 2003

10/689122

Tabassum Naqvi - Fremont CA, US
Riaz Rouhani - Concord CA, US
Peter Fung - Sunnyvale CA, US
Richard Eglen - Los Altos CA, US
Rajendra Singh - San Jose CA, US

G01N033/53

435/007900

Protein binding assays are provided for determining IPin a sample employing as reagents a conjugate of IPjoined at the 2-oxy through a bond or linking group to a detectable label and a truncated portion of the extracellular fragment of an IPR. The reagents are combined with the sample and the amount of IPdetermined by means of the detectable label. The conjugate with the enzyme donor fragment of -galactosidase or a fluorescer is specifically described.

2007001, Jan 18, 2007

Jun 20, 2006

11/471694

Keith Olson - Pleasanton CA, US
Peter Fung - Sunnyvale CA, US
Richard Eglen - Los Altos CA, US

DiscoveRx, Inc. - Fremont CA

C12Q 1/34

435018000

Mitosis of cells is determined, particularly in the presence of a candidate agent, using cells comprising members of an enzyme fragmentation complex pair, where one of the members is in the nucleus and the other member is in the cytoplasm. By growing the cells where mitosis may occur, one adds a substrate providing a detectable product, where the production of the detectable product is indicative of mitosis.